Pharma Business Week articles from March 2004

Pharma Business Week archives from March 2004

Specific fumagillin analogues suppress angiogenesis.
March 1, 2004... 2004 MAR 1 - (NewsRx.com & NewsRx.net) -- Specific fumagillin analogues suppress angiogenesis. According to a study from the United States, "modification of fumagillin was conducted to develop MetAP-2 inhibitors with desirable...

Pharmacokinetics of emtricitabine in HIV-infected children determined.
March 1, 2004... 2004 MAR 1 - (NewsRx.com & NewsRx.net) -- Investigators report the pharmacokinetics of emtricitabine in HIV-infected children in a recent issue of Antimicrobial Agents and Chemotherapy. "Emtricitabine (FTC; Emtriva), a potent deoxycytidine...

Mistrust limits minority representation in U.S. biomedical research.
March 1, 2004... 2004 MAR 1 - (NewsRx.com & NewsRx.net) -- Medical peer reviews are increasingly highlighting the inadequacy of minority representation in biomedical research, according to research from Frost & Sullivan. Ethnic minorities - African...

Major pharma unveils enhanced effort to combat counterfeit drugs.
March 1, 2004... 2004 MAR 1 - (NewsRx.com & NewsRx.net) -- Eli Lilly and Co. (LLY) announced an enhanced effort to combat the growing problem of counterfeit prescription drugs in the U.S. drug supply. The rise in counterfeit drugs has been exacerbated by...

Inhaled Alveair insulin achieves better bioavailability than IV injection.
March 1, 2004... 2004 MAR 1 - (NewsRx.com & NewsRx.net) -- Based on its preclinical data, Coremed, Inc., announced that its "needle-less" Alveair insulin pulmonary technology achieved better insulin bioavailability than intravenous injection of analog insulin....

Orphan drug designation granted by FDA for BCX-1777.
March 1, 2004... 2004 MAR 1 - (NewsRx.com & NewsRx.net) -- BioCryst Pharmaceuticals, Inc., (BCRX) announced that the U.S. Food and Drug Administration (FDA) granted orphan drug status to BCX-1777, the company's purine nucleoside phosphorylase (PNP) inhibitor...

FDA approves Orthovisc; Anika to receive $20M milestone payment.
March 1, 2004... 2004 MAR 1 - (NewsRx.com & NewsRx.net) -- Anika Therapeutics, Inc., (ANIK) announced that it has received marketing approval from the U.S. Food and Drug Administration (FDA) for Orthovisc, a highly purified, high molecular weight form of...

FDA approves Syneron Aurora for dermatological use.
March 1, 2004... 2004 MAR 1 - (NewsRx.com & NewsRx.net) -- Syneron Medical, Ltd., and its North American subsidiary Syneron, Inc., announced that the U.S. Food and Drug Administration (FDA) has granted 510K marketing clearance to Syneron's Aurora AC system for...

FDA urged to crack down on Internet sales of isotretinoin.
March 1, 2004... 2004 MAR 1 - (NewsRx.com & NewsRx.net) -- In a letter sent to the U.S. Food and Drug Administration (FDA), the American Academy of Dermatology Association (AADA) called on the FDA to halt Internet sales of isotretinoin, commonly known as...

Bone is a target for the antidiabetic compound rosiglitazone.
March 1, 2004... 2004 MAR 1 - (NewsRx.com & NewsRx.net) -- Bone is a target for the antidiabetic compound rosiglitazone. According to a study from the United States, "Rosiglitazone is an FDA-approved oral antidiabetic agent for the treatment of type 2...

Moving non-sedating antihistamines to third-tier status yields greatest savings.
March 1, 2004... 2004 MAR 1 - (NewsRx.com & NewsRx.net) -- Health plan sponsors that did not cover over-the-counter (OTC) Claritin (loratadine) and moved other prescription non-sedating antihistamine (NSA) drugs to third-tier status under a three-tier drug...

Scientists identify compound that may offer new Alzheimer treatment.
March 1, 2004... 2004 MAR 1 - (NewsRx.com & NewsRx.net) -- Samaritan Pharmaceuticals Inc. (SPHC) and Samaritan Research Labs, Georgetown University, announced that its research, published in the journal Steroids suggests that 22R-hydroxycholesterol derivatives...

Final efficacy results awaited as ALS trial of Ikomio moves forward.
March 1, 2004... 2004 MAR 1 - (NewsRx.com & NewsRx.net) -- ExonHit Therapeutics, a privately held drug discovery company, announced it has received recommendation by an independent Data Safety Monitoring Board (DSMB) to continue its clinical trial for Ikomio, a...

Phase III trial initiated to explore use of Humira.
March 1, 2004... 2004 MAR 1 - (NewsRx.com & NewsRx.net) -- Abbott Laboratories (ABT) announced the initiation of a global phase III study evaluating the potential of Humira (adalimumab) in treating ankylosing spondylitis. Ankylosing spondylitis (AS), or...

Anti-infective technology licensed to GMP.
March 1, 2004... 2004 MAR 1 - (NewsRx.com & NewsRx.net) -- The Procter & Gamble Co. (PG) and GMP Cos., Inc. announced that P&G has licensed to GMP its newly developed, topical anti-infective technology for exclusive worldwide use in medical settings and...

Structure of key autoimmune disease target discovered.
March 1, 2004... 2004 MAR 1 - (NewsRx.com & NewsRx.net) -- Xencor reported the structure of BAFF, also called BLyS or TALL-1, a key regulator of immune function and an important target in autoimmune disease. Scientists from Xencor demonstrated that BAFF's...

Avian flu virus continues to spread in Asian countries.
March 1, 2004... 2004 MAR 1 - (NewsRx.com & NewsRx.net) -- Despite massive efforts to stamp out the virulent avian influenza virus, the disease continues to spread in poultry-producing areas in some Asian countries, the UN Food and Agriculture Organization...

Pediatric bipolar disorder has unique symptoms.
March 1, 2004... 2004 MAR 1 - (NewsRx.com & NewsRx.net) -- For too many years, symptoms of severe moodiness in children were dismissed as being due to attention deficit disorder or poor parenting. A dramatic shift has led to greater recognition of bipolar...

FDA accepts NDA with priority review for RSR13.
March 1, 2004... 2004 MAR 1 - (NewsRx.com & NewsRx.net) -- Allos Therapeutics, Inc., (ALTH) announced that the Division of Oncology Drug Products at the U.S. Food and Drug Administration (FDA) has accepted for review the company's New Drug Application (NDA)...

New estrogen inhibitor in phase II development.
March 1, 2004... 2004 MAR 1 - (NewsRx.com & NewsRx.net) -- Ascend Therapeutics, Inc., announced that it has obtained exclusive North American development, marketing and commercialization rights to the developmental pharmaceutical product, TamoGel...

Biotech begins the year with a bang.
March 1, 2004... 2004 MAR 1 - (NewsRx.com & NewsRx.net) -- "Bolstered by good news at the clinic as well as the announcement of a number of promising collaborations, biotech's appeal on Wall Street grew significantly stronger in January," said G. Steven...

Diagnostics company goes public.
March 1, 2004... 2004 MAR 1 - (NewsRx.com & NewsRx.net) -- Motion DNA Corp. (MOTD) became a publicly traded company January, 30, 2004. The board of directors unanimously agreed to take the company public on the OTC in a meeting held January 19, 2004. ...

Drug discovery company announces 2003 financial results, research collaboration.
March 1, 2004... 2004 MAR 1 - (NewsRx.com & NewsRx.net) -- Pharmacopeia, Inc., (PCOP) announced results for the fourth quarter and 12 months ended December 31, 2003, and announced that it has entered into a research collaboration with Taiho Pharmaceutical Co....

Inspection of drug-eluting stent facility completed; finances reported.
March 1, 2004... 2004 MAR 1 - (NewsRx.com & NewsRx.net) -- Boston Scientific Corporation (BSX) announced that an inspection team from the U.S. Food and Drug Administration (FDA) has completed its inspection of the company's drug-eluting stent manufacturing...

NASDAQ completes favorable review of company's new board.
March 1, 2004... 2004 MAR 1 - (NewsRx.com & NewsRx.net) -- eXegenics, Inc., (EXEG) announced that NASDAQ has notified eXegenics that a NASDAQ internal staff review concluded that the newly constituted board and its audit committee satisfy the independent...

Small molecule drug company files registration statement for IPO.
March 1, 2004... 2004 MAR 1 - (NewsRx.com & NewsRx.net) -- Metabasis Therapeutics, Inc., announced in February 2004 that it has filed a registration statement with the U.S. Securities and Exchange Commission relating to an initial public offering (IPO) of its...

Drug discovery company announces name change, new appointments.
March 1, 2004... 2004 MAR 1 - (NewsRx.com & NewsRx.net) -- Semafore Pharmaceuticals, Inc., announced the company's name change from ComChem Technologies to better reflect the company's strategic focus. Semafore's therapeutic programs are based on...

House of Brussels forms medical research subsidiary.
March 1, 2004... 2004 MAR 1 - (NewsRx.com & NewsRx.net) -- House of Brussels Chocolates (HBSL), through its CEO Grant Petersen, announced several major corporate developments. Firstly, HBSL has incorporated a subsidiary company, ChocoMed, Inc., to act as...

Pharmaceutical company announces dismissal of all lawsuits.
March 1, 2004... 2004 MAR 1 - (NewsRx.com & NewsRx.net) -- Titan Pharmaceuticals, Inc. (TTP) announced that all of the class action and derivative lawsuits filed against the company have been dismissed without prejudice. In every case, the plaintiffs...

New research may lead to orally administered small-molecule cancer drug.
March 1, 2004... 2004 MAR 1 - (NewsRx.com & NewsRx.net) -- New insights into a key cancer pathway - known as p53 - have been uncovered by scientists at Roche. In a paper published in the February 6 issue of Science and Sciencexpress, for the first time,...

Fourth phase II trial initiated for new stem cell transplantation drug candidate.
March 1, 2004... 2004 MAR 1 - (NewsRx.com & NewsRx.net) -- AnorMED, Inc., (AOM) announced the initiation of its fourth phase II clinical trial to evaluate AMD3100 as a new stem cell transplantation drug candidate for cancer patients. Clinical data to date...

Update provided on Polymer Platinate AP5346 program.
March 1, 2004... 2004 MAR 1 - (NewsRx.com & NewsRx.net) -- Access Pharmaceuticals, Inc., (AKC) provided an update on the status of its AP5346 Polymer Platinate Program, including the patent status, preclinical data, and the progress of the phase I clinical...

Publication points to increasing use of HPV testing in cervical cancer screening.
March 1, 2004... 2004 MAR 1 - (NewsRx.com & NewsRx.net) -- The first consensus guidance on the most effective way to use HPV DNA testing for cervical cancer screening has been published in the February issue of Obstetrics & Gynecology, announced Digene Corp....

FDA approves Spiriva HandiHaler.
March 1, 2004... 2004 MAR 1 - (NewsRx.com & NewsRx.net) -- Boehringer Ingelheim Pharmaceuticals, Inc., announced that the U.S. Food and Drug Administration (FDA) has approved Spiriva HandiHaler (tiotropium bromide inhalation powder) for the long-term,...

Industry experts form patient recruiting firm for clinical trials.
March 1, 2004... 2004 MAR 1 - (NewsRx.com & NewsRx.net) -- Integrated Clinical Trial Services (ICTS) has been formed by a team of industry experts as a more effective approach for pharmaceutical, biotech, and medical device companies to enroll patients in...

Axeda DRM software licensed for proactive remote service.
March 1, 2004... 2004 MAR 1 - (NewsRx.com & NewsRx.net) -- The Diagnostics Division of Bayer HealthCare, LLC, a member of the Bayer Group (BAY), and Axeda Systems, Inc., (XEDA), a provider of device relationship management (DRM) enterprise software and...

Biotech companies sign licensing deal for protein therapeutics development.
March 1, 2004... 2004 MAR 1 - (NewsRx.com & NewsRx.net) -- Chromos Molecular Systems, Inc., (CHR) and AviGenics, Inc., announced that they have signed a license agreement under which AviGenics has acquired exclusive rights to Chromos' ACE System to generate...

Co-brand partnership agreement signed with 3M.
March 1, 2004... 2004 MAR 1 - (NewsRx.com & NewsRx.net) -- Alltracel Pharmaceuticals, plc, (AP.L) announced a material supply, technology transfer and co-brand partnership program with the Health Care division of 3M (MMM), the global diversified technology...

Companies ink agreement to develop MicroPyramid-based vaccine delivery.
March 1, 2004... 2004 MAR 1 - (NewsRx.com & NewsRx.net) -- NanoPass Technologies, Ltd., has signed an agreement with GlaxoSmithKline's Biopharmaceutical Centre of Excellence for Drug Discovery (GSK) to develop NanoPass' MicroPyramid technology for the delivery...

Company expands its proteomic capabilities through agreement with Novartis.
March 1, 2004... 2004 MAR 1 - (NewsRx.com & NewsRx.net) -- GeneProt, Inc., announced that it has amended its scientific collaboration with Novartis Pharma, AG. The new collaboration will maximize the value from the synergy of GeneProt's industrial-scale...

Deal signed with Amylin Pharmaceuticals to develop Omniclonal antibodies.
March 1, 2004... 2004 MAR 1 - (NewsRx.com & NewsRx.net) -- Biosite Incorporated (BSTE) has entered into a discovery collaboration with Amylin Pharmaceuticals, Inc., under which Biosite intends to develop Omniclonal antibodies for targets provided by Amylin. ...

Device firm to develop immunochromatographic rapid test devices.
March 1, 2004... 2004 MAR 1 - (NewsRx.com & NewsRx.net) -- AspenBio, Inc., (APNB) announced that it has created a Lateral Flow Division for the development, manufacturing and distribution of immunochromatographic rapid test devices. The devices determine...

Distribution agreement signed for Testim testosterone gel in Canada.
March 1, 2004... 2004 MAR 1 - (NewsRx.com & NewsRx.net) -- Auxilium Pharmaceuticals, Inc., and Bayer, Inc., a division of Bayer AG (BAY), announced a distribution agreement for marketing of Auxilium's Testim 1% testosterone gel in Canada. Testim has been...

Drug discovery and development collaboration amended.
March 1, 2004... 2004 MAR 1 - (NewsRx.com & NewsRx.net) -- Vertex Pharmaceuticals Incorporated (VRTX) announced that Vertex and Novartis Pharma AG have amended their collaboration directed at targets in the protein kinase gene family. The revised agreement...

Genetronics announces strategic alliance.
March 1, 2004... 2004 MAR 1 - (NewsRx.com & NewsRx.net) -- Genetronics Biomedical Corp. (GEB) announced an agreement with RMR Technologies, LLC, (RMR), where Genetronics may commercialize RMR's electroporation methods and devices on a worldwide exclusive basis....

Labopharm to develop once-daily formulation of trazodone.
March 1, 2004... 2004 MAR 1 - (NewsRx.com & NewsRx.net) -- Labopharm, Inc., (DDS) has signed an agreement with Gruppo Angelini under which Labopharm will formulate a once-daily version of the antidepressant trazodone hydrochloride (trazodone) for global...

Marketing agreement signed for promotion of aspergillus test.
March 1, 2004... 2004 MAR 1 - (NewsRx.com & NewsRx.net) -- Bio-Rad Laboratories, Inc., (BIO; BIOb), a multinational manufacturer and distributor of life science research products and clinical diagnostics, announced that it has entered into a marketing agreement...

Milestone payment made in anticipation of NDA filing of Clofarabine.
March 1, 2004... 2004 MAR 1 - (NewsRx.com & NewsRx.net) -- Bioenvision, Inc., (BIV) announced that it has signed an agreement with Ilex Products, Inc., a wholly owned subsidiary of Ilex Oncology, Inc., (ILXO), in which Bioenvision has converted Ilex's option to...

Partnership to develop new treatment for tropical disease.
March 1, 2004... 2004 MAR 1 - (NewsRx.com & NewsRx.net) -- Roche and AEterna Laboratories, Inc., (AEL; AELA) announced a partnership for the marketing in Brazil of Impavido (Miltefosine), the breakthrough oral therapy of leishmaniasis. The agreement was...

Rutgers enters partnership to explore science of taste buds.
March 1, 2004... 2004 MAR 1 - (NewsRx.com & NewsRx.net) -- Linguagen Corp., a company focused on in the development of ingredients used to improve the taste of food, beverages, and pharmaceutical products, has partnered with scientists at Rutgers, The State...

Supply agreement signed with Hepatotech for preservation solutions.
March 1, 2004... 2004 MAR 1 - (NewsRx.com & NewsRx.net) -- BioLife Solutions, Inc., (BLFS) announced that it has signed a multiyear supply agreement with Pittsboro, North Carolina-based Hepatotech, Inc., a privately held manufacturer and distributor of...

Xeloda shows promising tolerability results in colon cancer study patients.
March 1, 2004... 2004 MAR 1 - (NewsRx.com & NewsRx.net) -- A safety analysis from a major phase III study involving patients with early stage colon cancer shows that those receiving oral Xeloda (capecitabine) had promising tolerability results compared to those...

FDA approves Erbitux for metastatic disease.
March 1, 2004... 2004 MAR 1 - (NewsRx.com & NewsRx.net) -- The U.S. Food and Drug Adminstration (FDA) has approved Erbitux (cetuximab) to treat patients with advanced colorectal cancer that has spread to other parts of the body. Erbitux is the first...

Hydrangeae dulcis folium suppresses liver injury in rats.
March 1, 2004... 2004 MAR 1 - (NewsRx.com & NewsRx.net) -- Hydrangeae dulcis folium suppresses liver injury in rats. "Hydrangeae dulcis folium, the fermented and dried leaves of Hydrangea macrophylla SER. var. thunbergii MAKINO, suppressed...

PEECH trial reaches enrollment target.
March 1, 2004... 2004 MAR 1 - (NewsRx.com & NewsRx.net) -- Vasomedical, Inc., (VASO) announced that the patient enrollment target has been met in the PEECH (Prospective Evaluation of EECP in Congestive Heart Failure) trial, the company's pivotal clinical trial...

Study of adult stem cell reimplantation initiated.
March 1, 2004... 2004 MAR 1 - (NewsRx.com & NewsRx.net) -- By harvesting and reimplanting a patient's own stem cells, physicians hope to grow new blood vessels to relieve the disabling chest pain of severely ill cardiac patients. Physicians at Caritas St....

CAP nanotechnology product developments reported.
March 1, 2004... 2004 MAR 1 - (NewsRx.com & NewsRx.net) -- BioSante Pharmaceuticals, Inc., (BPA) announced an update on recent developments of its calcium phosphate-based nanotechnology (CAP). "To date we have made significant progress in development of...

Nucleic acid detection technology developer forms subsidiary.
March 1, 2004... 2004 MAR 1 - (NewsRx.com & NewsRx.net) -- Centrex, Inc., (CNEX) announced that to enhance the company's ability to accelerate the development of the company's Single Molecule Nucleic Acid Detection (SMD) technology, Centrex, Inc., in...

Positive preclinical data reported on GLP-1 and Gastrin combination therapy.
March 1, 2004... 2004 MAR 1 - (NewsRx.com & NewsRx.net) -- Transition Therapeutics Inc. (TTH) announced positive preclinical efficacy data for a second islet neogenesis therapy, GLP1-I.N.T. Following a short course of treatments, blood glucose levels...

New drug researched for war on diabetes.
March 1, 2004... 2004 MAR 1 - (NewsRx.com & NewsRx.net) -- A central Texas doctor is directing a national study on a new diabetes drug that researchers hope can prevent onset of the disease. Dr. Ralph DeFronzo, a researcher at the Texas Diabetes Institute...

Report shows 56% of opiate dependencies begin through legal prescriptions.
March 1, 2004... 2004 MAR 1 - (NewsRx.com & NewsRx.net) -- The Waismann Institute released findings of its 2004 Opiate Dependency Report, which shows that 56% of patients' opiate dependencies began with medication prescribed by their doctors. The findings...

Fluidigm granted nonexclusive sublicense to nanovolume crystallization patents.
March 1, 2004... 2004 MAR 1 - (NewsRx.com & NewsRx.net) -- Fluidigm Corp. and Syrrx, Inc., announced that Fluidigm has obtained from Syrrx license rights directed to the submicroliter crystallization of proteins. The terms of the agreement were not...

Telepathology product installed for drug discovery and research.
March 1, 2004... 2004 MAR 1 - (NewsRx.com & NewsRx.net) -- Trestle Holdings Inc. (TLHO) has further expanded its relationship with Pfizer, Inc. (PFE) under which the company installed an additional MedMicro telepathology product at the Pfizer research center in...

Positive results reported from phase II study of lidocaine vaginal gel.
March 1, 2004... 2004 MAR 1 - (NewsRx.com & NewsRx.net) -- Columbia Laboratories (COB) announced the successful completion of a trial evaluating the effect of Columbia's lidocaine bioadhesive vaginal gel on uterine contractions and pain. Trial results...

Studies show tacrolimus is more effective than pimecrolimus.
March 1, 2004... 2004 MAR 1 - (NewsRx.com & NewsRx.net) -- Interim data from three studies presented at the 62nd Annual Meeting of the American Academy of Dermatology demonstrate that tacrolimus ointment is more effective than pimecrolimus cream in the...

Pharmaceutical company announces acquisition of epilepsy product candidate.
March 1, 2004... 2004 MAR 1 - (NewsRx.com & NewsRx.net) -- Xcel Pharmaceuticals, Inc., has acquired from Viatris GmbH and Co. exclusive worldwide product rights to retigabine, a late-stage development product candidate for the treatment of epilepsy. Xcel...

Results announced for TA-1790 phase II head-to-head study with Viagra.
March 1, 2004... 2004 MAR 1 - (NewsRx.com & NewsRx.net) -- VIVU.S., Inc., (VVU.S.) announced data on TA-1790, its oral phosphodiesterase type 5 (PDE5) inhibitor for the treatment of erectile dysfunction (ED). The phase II head-to-head at-home study...

FDA accepts filing for Sculptra.
March 1, 2004... 2004 MAR 1 - (NewsRx.com & NewsRx.net) -- Dermik Laboratories, the U.S. dermatology arm of Aventis (AVE), announced that the U.S. Food and Drug Administration (FDA) has accepted for filing and granted expedited review of the company's Premarket...

Anal fissure drug maker announces investment by SJ Strategic Investments.
March 1, 2004... 2004 MAR 1 - (NewsRx.com & NewsRx.net) -- Cellegy Pharmaceuticals, Inc., (CLGY) announced that SJ Strategic Investments has increased its ownership position in Cellegy to 29.1%. SJ Strategic Investments is a family investment vehicle owned...

Biopharmaceutical company files $1B universal shelf registration statement.
March 1, 2004... 2004 MAR 1 - (NewsRx.com & NewsRx.net) -- Cephalon, Inc., (CEPH) announced that it has filed a $1.0 billion universal shelf registration statement with the U.S. Securities and Exchange Commission covering the issuance and sale, from time to...

Biopharmaceutical company raises $37M to advance clinical development programs.
March 1, 2004... 2004 MAR 1 - (NewsRx.com & NewsRx.net) -- XenoPort, Inc., has completed a private equity financing totaling $37 million. The financing was led by Granite Global Ventures of Menlo Park, California. Other new investors include AIG SunAmerica...

Biopharmaceutical company receives $5M equity investment.
March 1, 2004... 2004 MAR 1 - (NewsRx.com & NewsRx.net) -- PPD, Inc., (PPDI) has made a $5 million equity investment in Accentia, Inc. Under the terms of the agreements, PPD purchased shares of Accentia's Series E convertible preferred stock. In addition to...

Biopharmaceutical company reports net loss of $0.40 per share.
March 1, 2004... 2004 MAR 1 - (NewsRx.com & NewsRx.net) -- BioMarin Pharmaceutical, Inc., (BMRN) announced financial results for its fourth quarter ended December 31, 2003. The net loss was $25.7 million ($0.40 per share) for the fourth quarter of 2003...

Biotech company increases share capital as a result of employee warrants.
March 1, 2004... 2004 MAR 1 - (NewsRx.com & NewsRx.net) -- Genmab A/S announced that it is increasing its share capital by 183,500 shares as a consequence of the exercise of employee warrants. This increase is effected without any preemption rights for the...

Biotech company reports loss of $0.22 per share.
March 1, 2004... 2004 MAR 1 - (NewsRx.com & NewsRx.net) -- Array BioPharma, Inc., (ARRY) reported financial results for the second quarter of fiscal 2004, ended December 31, 2003. During the second quarter of fiscal 2004, Array reported total revenue of...

Cachexia drug developer secures $12M in financing.
March 1, 2004... 2004 MAR 1 - (NewsRx.com & NewsRx.net) -- Advanced Viral Research Corp. (ADVR) announced that it entered into an agreement with James Dicke II and his son James Dicke III whereby ADVR shall sell to the two purchasers an aggregate of 120,000,000...

Diabetes drug maker closes private placement funding.
March 1, 2004... 2004 MAR 1 - (NewsRx.com & NewsRx.net) -- Robert Rieveley, president of Biotech Holdings (BIO.V; BIOHF), said that the company has now closed $266,000 of private placements announced January 27, 2004. "These funds allow us to complete all...

Drug discovery company reports 2003 financial results.
March 1, 2004... 2004 MAR 1 - (NewsRx.com & NewsRx.net) -- Seattle Genetics, Inc., (SGEN) reported results for the fourth quarter and year ended December 31, 2003. Revenues for the fourth quarter of 2003 were $1.3 million, compared with $635,000 in the...

Enzyme company completes $9.2 million financing.
March 1, 2004... 2004 MAR 1 - (NewsRx.com & NewsRx.net) -- Hyalozyme Therapeutics, Inc., has completed a $9.2 million financing led by Grove Capital. The financing also included an option to purchase an additional $15.9 million in warrants callable by...

Gates Foundation commits $82.9 million to develop new tuberculosis vaccines.
March 1, 2004... 2004 MAR 1 - (NewsRx.com & NewsRx.net) -- The Bill & Melinda Gates Foundation has announced an $82.9 million grant to the Aeras Global TB Vaccine Foundation to support development of new vaccines to prevent tuberculosis (TB), a disease that...

Genomics company completes $25.5M public offering of common stock.
March 1, 2004... 2004 MAR 1 - (NewsRx.com & NewsRx.net) -- Targeted Genetics Corporation (TGEN) has completed a public offering of approximately 10.9 million shares of its common stock at a price of $2.35 per share to institutional investors, for gross proceeds...

Gould named chief financial officer at drug delivery company.
March 1, 2004... 2004 MAR 1 - (NewsRx.com & NewsRx.net) -- Atrix Laboratories, Inc., (ATRX) announced the appointment of Gregory A. Gould to the position of chief financial officer. "We are pleased to welcome Greg to our management team," said David R....

Imaging company announces approval of stock issuance.
March 1, 2004... 2004 MAR 1 - (NewsRx.com & NewsRx.net) -- Elbit Medical Imaging, Ltd., (EMITF) announced that its board of directors had approved an issuance of 623,362 ordinary shares of the company to Triple-S Holdings N.V. (the offeree). The private...

Immunotherapeutics company prices $52.5M public offering.
March 1, 2004... 2004 MAR 1 - (NewsRx.com & NewsRx.net) -- Antigenics, Inc., (AGEN) announced that it has priced its previously announced public offering of common stock. In the offering, Antigenics is selling 5,000,000 shares at a price to the public of...